Clinical and Experimental Medicine, Journal Year: 2025, Volume and Issue: 25(1)
Published: April 10, 2025
Language: Английский
Biomolecules, Journal Year: 2025, Volume and Issue: 15(1), P. 144 - 144
Published: Jan. 18, 2025
Hepatocellular carcinoma (HCC) is among the most aggressive and lethal human tumors. Many functional studies have demonstrated role of non-coding RNAs (ncRNA), particularly microRNAs (miRNA), in regulation hepatocarcinogenesis driving pathways. MiR-125a-5p (miR-125a) has been consistently reported as an oncosuppressive miRNA, vivo vitro. However, its HCC relevant targets molecular mechanisms are still largely unknown. Here, a genome-wide perspective whole miR-125a targetome achieved. In particular, two different cell lines were subjected to miRNA boosting by mimic transfections, consequently many genes de-regulated, observed transcriptomic approach. The merging down-regulated with results from bioinformatic predictive tools yielded number candidate direct that further experimentally validated luciferase-based reporter assays. Different novel found, particular ARID3A, CCNJ, LIPA, NR6A1, NUP210, oncogenes various tumors here also related through regulation. RNA interactions investigated this work could pave way piece together regulatory networks governed impacting on hepatocarcinogenesis, be exploited future for identifying biomarkers therapeutic HCC.
Language: Английский
Citations
0
Molecular Therapy — Nucleic Acids, Journal Year: 2025, Volume and Issue: 36(2), P. 102494 - 102494
Published: Feb. 21, 2025
RNA activation (RNAa), a gene regulatory mechanism mediated by small activating RNAs (saRNAs) and microRNAs (miRNAs), has significant implications for therapeutic applications. Unlike interfering (siRNA), which is known silencing in interference (RNAi), synthetic saRNAs can stably upregulate target expression at the transcriptional level through assembly of RNA-induced (RITA) complex. Moreover, dual functionality endogenous miRNAs RNAa (hereafter referred to as mi-RNAa) reveals their complex role cellular processes disease pathology. Emerging studies suggest saRNAs' potential novel modality diseases such metabolic disorders, hearing loss, tumors, Alzheimer's. Notably, MTL-CEBPA, first saRNA drug candidate, shows promise hepatocellular carcinoma treatment, while RAG-01 being explored non-muscle-invasive bladder cancer, highlighting clinical advancements RNAa. This review synthesizes our current understanding mechanisms highlights recent study mi-RNAa development saRNAs.
Language: Английский
Citations
0
Discover Oncology, Journal Year: 2025, Volume and Issue: 16(1)
Published: March 8, 2025
Hepatocellular carcinoma (HCC) is one of the leading causes cancer-related death worldwide. Although many therapeutic modalities have been established for treating HCC patients, outcomes patients remain unsatisfactory. Development independent prognostic biomarkers thus an important need to allow early diagnosis and timely treatment. MicroRNAs (miRNAs) are most studied class small non-coding RNAs. It has shown that miRNAs play essential roles in multiple steps tumorigenesis progression. Furthermore, baseline expression levels altered tumor tissues blood circulation patients. Therefore, emerged as prediction prognosis. This review provides a comprehensive literature-based summary tissue circulating miRNA with significance HCC.
Language: Английский
Citations
0
Gene, Journal Year: 2025, Volume and Issue: unknown, P. 149459 - 149459
Published: March 1, 2025
Language: Английский
Citations
0
Clinical and Experimental Medicine, Journal Year: 2025, Volume and Issue: 25(1)
Published: April 10, 2025
Language: Английский
Citations
0